Skip to Content
A35 / P35
NCODA Oncology and Hematology Meeting Abstracts | Volume 1 | Supplement 1
Publication Date: June 15, 2026

Upcoming Medicare Part D changes for 2026

Authors:

Vonda McClendon, CPhT1

Organization / Company:

1Texas Oncology

NCODA Oncol Hematol Meet Abstr. 2026;1(suppl 1):abstr 35.

Background:

Medicare Part D is a government program, which was enacted in 2006. This program helps Medicare beneficiaries pay for prescription drugs. It’s an optional, voluntary benefit offered through private insurance companies approved by the federal government. However, penalties may be incurred if patients do not have credible coverage. Part D helps cover the cost of prescription medications, including both brand-name and generic drugs, that are not typically covered by Medicare Part A or Part B.

 

Objectives:
  • Explain the 2026 deductible and new maximum prescription drug out-of-pocket (OOP) indexed for inflation.
  • Define the prior authorization changes coming to six states in 2026.
  • Update on the cancer drugs included on the 2026 maximum fair price (MFP) negotiated price list.
  • Highlight Medicare Prescription Payment Plan (M3P) enhancement and Medicare Advantage enrollment recommendations.

 

Methods:

Proposed Part D updates to the Medicare programs for 2026 are intended to improve benefits to Medicare beneficiaries. These changes will be implemented for all Medicare Part D beneficiaries beginning January 1, 2026, with an emphasis on increases in annual prescription drug deductibles and the maximum out-of-pocket (MOOP) limit, as well as modifications to drug formularies.

 

Results & Impact:

With the 2026 changes Part D, the Medicare prescription drug programs are implementing them in an effort to keep medications affordable and accessible for its enrollees. These changes are in accordance with the original guidelines of the Healthcare Affordability Act of 2025.

 

Conclusions:

Under Centers for Medicare and Medicaid Services (CMS) supervision, these upcoming changes are part of the broader Medicare Part D redesign stemming from the Inflation Reduction Act (IRA).

Funding: Not applicable.

A35 / P35